Search filters

Filters
Clear All

Phase

  • 4
  • 9
  • 14
  • 2
  • 5
  • 36
  • 17
  • 1
  • 35
  • 35
  • 1

Found 36 Lymphoma trials

A listing of Lymphoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

18 years - 99 years
All genders
Phase 2
The purpose of this study is to see whether the addition of ixazomib to ibrutinib chemotherapy is effective in treating people who have relapsed or refractory mantle cell lymphoma and to examine the side effects associated with ixazomib in combination with ibrutinib.
18 years - 99 years
All genders
Phase 2
This research study is being conducted to assess the safety and efficacy of IPH4102, an investigative medication (medication not approved by the Food and Drug Administration (FDA) for subjects diagnosed with Sézary Syndrome (SS) or Mycosis Fungoides (MF) over the age of 18. Participants will be asked to complete the …
 RADVAX FOR RELAPSED/REFRACTORY HODGKIN LYMPHOMA: A PHASE II TRIAL OF NIVOLUMAB + LOW DOSE RADIOTHERAPY FOR INCOMPLETE RESPONDERS
99 years or below
All genders
Phase 2
This is a Phase II single-arm, single-site, open label clinical trial with r/r HL patients, aimed to determine whether a RadVax approach using low-dose RT added to nivolumab can improve response among patients who do not achieve a CR to nivolumab alone. The long-term goal is to develop an effective …
99 years or below
All genders
Phase 2
The study will assess how safe and well-tolerated a combination of the study drugs itacitinib and everolimus in patients with Hodgkin lymphoma. We also hope to learn how effective this experimental combination is in treating Hodgkin lymphoma, when given together.
99 years or below
All genders
Phase 2
To evaluate the efficacy of tisagenlecleucel therapy among adult patients with refractory or relapsed follicular lymphoma as measured by complete response rate determined by Independent Review Committee in the full analysis set based on Lugano 2014 classification response criteria.
99 years or below
All genders
Phase 1
This is a Phase 1/2, open-label, multicenter dose-escalation and dose-expansion trial evaluating the safety and tolerability of fimepinostat administered orally to patients with R/R lymphoma.
 A Randomized  Open Label Pilot Trial of a Biomarker Guided Strategy of Cardioprotection in Patients with Lymphoma or Breast Cancer Treated with Anthracyclines
18 years - 99 years
All genders
Phase 1
You will be receiving anthracycline-based chemotherapy (Adriamycin/doxorubicin) as part of your cancer treatment plan. Although anthracycline-based chemotherapy is effective in treating cancer, it can damage your heart. This study has two goals. The first goal is to see if we can identify who is most at risk for this heart …
 A DOUBLE BLIND  RANDOMIZED VEHICLE CONTROLLED  CROSSOVER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TOPICAL NALOXONE HYDROCHLORIDE LOTION  0.5%  FOR THE RELIEF OF PRURITUS IN PATIENTS WITH THE MYCOSIS FUNGOIDES (MF) FORM OF CUTANEOUS T-CELL LYMPHOMA (CTCL
99 years or below
All genders
Phase 3
This application is a request to execute a reliance agreement with Chesapeake an external IRB This study is being done to assess the efficacy and safety of Naloxone HCL Lotion 0.5% compared to Vehicle Lotion for the treatment of itching in patients with mycosis fungoides (MF), which is a type …
99 years or below
All genders
Phase 1
The purpose of the study is to find out if an engineered T-cell therapy (tisagenlecleucel) in combination with ibrutinib is safe and tolerable for people with relapsed and/or refractory diffuse large B-cell lymphoma.
 Phase I Trial of Programmed Allogeneic CRISPR-edited T cells (PACE) Gene Edited to Eliminate Endogenous TCR  HLA-class I and HLA-class II and Engineered to Express anti-CD19 Chimeric Antigen Receptor (PACE CART19) in Patients with Relapsed Or Refractory CD19+ Leukemia and Lymphoma
18 years - 99 years
All genders
Phase 1
Interventional
This research study is being conducted to evaluate an experimental drug called PACE CART19 in patients with leukemia or lymphoma. PACE CART19 consists of cells from a healthy donor that are genetically modified and designed to target your cancer.
21 - 30 of 36